Senti Biosciences (SNTI) Competitors $1.68 -0.02 (-1.18%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.66 -0.01 (-0.89%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI vs. CGC, FDMT, YMAB, OGI, ENGN, RAPT, CTMX, CYBN, SXTC, and CRBUShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Canopy Growth (CGC), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Organigram Global (OGI), enGene (ENGN), Rapt Therapeutics (RAPT), CytomX Therapeutics (CTMX), Cybin (CYBN), China SXT Pharmaceuticals (SXTC), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Its Competitors Canopy Growth 4D Molecular Therapeutics Y-mAbs Therapeutics Organigram Global enGene Rapt Therapeutics CytomX Therapeutics Cybin China SXT Pharmaceuticals Caribou Biosciences Senti Biosciences (NASDAQ:SNTI) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings. Do analysts rate SNTI or CGC? Senti Biosciences currently has a consensus price target of $8.50, indicating a potential upside of 405.95%. Given Senti Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Senti Biosciences is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Canopy Growth 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals and insiders believe in SNTI or CGC? 25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 1.3% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, SNTI or CGC? Senti Biosciences has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSenti BiosciencesN/AN/A-$52.79M-$10.84-0.15Canopy Growth$225.65M0.95-$429.86M-$4.04-0.26 Does the media favor SNTI or CGC? In the previous week, Canopy Growth had 3 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Canopy Growth and 0 mentions for Senti Biosciences. Canopy Growth's average media sentiment score of 0.51 beat Senti Biosciences' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media. Company Overall Sentiment Senti Biosciences Neutral Canopy Growth Positive Which has more risk and volatility, SNTI or CGC? Senti Biosciences has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Is SNTI or CGC more profitable? Senti Biosciences has a net margin of 0.00% compared to Canopy Growth's net margin of -195.76%. Canopy Growth's return on equity of -88.54% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Senti BiosciencesN/A -177.24% -67.38% Canopy Growth -195.76%-88.54%-40.78% SummarySenti Biosciences beats Canopy Growth on 9 of the 15 factors compared between the two stocks. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.34M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-0.1517.6228.6723.80Price / SalesN/A179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book0.328.508.275.55Net Income-$52.79M-$55.06M$3.24B$259.03M7 Day Performance-12.95%-3.98%-3.69%-4.59%1 Month Performance-23.98%9.59%4.33%4.46%1 Year Performance-18.45%6.72%25.95%18.03% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences1.7663 of 5 stars$1.68-1.2%$8.50+406.0%-22.2%$44.34MN/A-0.154CGCCanopy Growth0.6272 of 5 stars$1.12+2.8%N/A-84.5%$200.41M$225.65M-0.283,150News CoverageUpcoming EarningsFDMT4D Molecular Therapeutics2.5461 of 5 stars$4.24+0.5%$29.56+597.1%-62.7%$195.49M$40K-1.33120News CoverageUpcoming EarningsAnalyst ForecastGap UpYMABY-mAbs Therapeutics2.302 of 5 stars$4.33+0.5%$15.60+260.3%-61.1%$195.17M$87.68M-6.77150News CoverageShort Interest ↑OGIOrganigram Global1.1589 of 5 stars$1.46+0.7%N/A-15.3%$194.21M$117.47M14.60860News CoverageENGNenGene3.4672 of 5 stars$3.85+1.6%$23.29+504.8%-56.5%$193.69MN/A-2.3331RAPTRapt Therapeutics4.0217 of 5 stars$11.70+0.2%$19.80+69.2%-58.0%$193.14M$1.53M-0.6180Upcoming EarningsAnalyst UpgradeGap DownCTMXCytomX Therapeutics4.0091 of 5 stars$2.38-0.4%$5.33+124.1%+75.4%$192.28M$147.56M4.96170News CoverageUpcoming EarningsAnalyst ForecastCYBNCybin2.5864 of 5 stars$8.03-3.5%$85.00+958.5%N/A$191.56MN/A-1.8350High Trading VolumeSXTCChina SXT Pharmaceuticals0.4957 of 5 stars$1.62-1.3%N/A-80.3%$191.04M$1.93M0.0090News CoverageAnalyst UpgradeCRBUCaribou Biosciences2.4417 of 5 stars$2.07+1.0%$8.50+310.6%-12.9%$190.66M$9.99M-1.28100Upcoming EarningsGap Down Related Companies and Tools Related Companies Canopy Growth Alternatives 4D Molecular Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Organigram Global Alternatives enGene Alternatives Rapt Therapeutics Alternatives CytomX Therapeutics Alternatives Cybin Alternatives China SXT Pharmaceuticals Alternatives Caribou Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNTI) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNTI Stock Alerts